ChemoCentryx, Inc.
CCXI · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $11,763 | $5,459 | $2,611 | $17,691 |
| % Growth | 115.5% | 109.1% | -85.2% | – |
| Cost of Goods Sold | $803 | $205 | $302 | $0 |
| Gross Profit | $10,960 | $5,254 | $2,309 | $17,691 |
| % Margin | 93.2% | 96.2% | 88.4% | 100% |
| R&D Expenses | $14,355 | $17,476 | $18,771 | $19,948 |
| G&A Expenses | $0 | $26,011 | $55,558 | $19,598 |
| SG&A Expenses | $28,179 | $26,011 | $23,423 | $19,598 |
| Sales & Mktg Exp. | $0 | $0 | -$32,135 | $0 |
| Other Operating Expenses | $0 | $0 | $468 | -$52 |
| Operating Expenses | $42,534 | $43,487 | $42,662 | $39,494 |
| Operating Income | -$31,065 | -$38,011 | -$45,275 | -$21,803 |
| % Margin | -264.1% | -696.3% | -1,734% | -123.2% |
| Other Income/Exp. Net | -$77 | -$375 | -$477 | -$504 |
| Pre-Tax Income | -$31,651 | -$38,608 | -$40,528 | -$22,307 |
| Tax Expense | $586 | $597 | -$4,747 | $0 |
| Net Income | -$32,237 | -$39,205 | -$35,781 | -$22,307 |
| % Margin | -274.1% | -718.2% | -1,370.4% | -126.1% |
| EPS | -0.45 | -0.55 | -0.51 | -0.32 |
| % Growth | 18.2% | -7.8% | -59.4% | – |
| EPS Diluted | -0.45 | -0.55 | -0.51 | -0.32 |
| Weighted Avg Shares Out | 71,234 | 70,835 | 70,111 | 69,894 |
| Weighted Avg Shares Out Dil | 71,234 | 70,835 | 70,111 | 69,894 |
| Supplemental Information | – | – | – | – |
| Interest Income | $509 | $222 | $166 | $164 |
| Interest Expense | $586 | $597 | -$4,747 | $668 |
| Depreciation & Amortization | $1,024 | $1,017 | $1,016 | $1,003 |
| EBITDA | -$30,041 | -$36,994 | -$44,259 | -$20,636 |
| % Margin | -255.4% | -677.7% | -1,695.1% | -116.6% |